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INTRODUCTION

After receiving a testicular cancer diagnosis in 2012, Russell “Rusty”
Williams, a West Virginia native, turned to cannabis to alleviate the crippling
side effects of chemotherapy.1 Rusty, like other chemotherapy patients,2 found
that cannabis helped to alleviate the pain and nausea that inevitably accompanies
chemotherapy. Frustrated by his home state’s intolerance of the medicine that
Rusty claims saved his life, Rusty began working as a medical cannabis advocate
to lobby for a change in West Virginia cannabis law.3 His efforts helped realize
his goal and real legislative change occurred. Rusty now serves as a patient
advocate on the state’s Medical Cannabis Advisory Board where he encourages
broader cannabis access, increased local business opportunities, and cannabis
decriminalization.4
With the passage of the Medical Cannabis Act (“the Act”) in 2017, West
Virginia joined 32 states and the District of Columbia in allowing for the use of
medical cannabis under state law.5 This Act marked a dramatic shift in the legal
status of medical cannabis under state law. Passage of the Act was illustrative of
the changing public perception and increasing support for cannabis.6 However,
despite national public support in favor of legalized cannabis, West Virginia’s
Medical Cannabis Act remains in contravention to federal laws strictly
prohibiting cannabis possession.7 Likely thanks in large part to historical state
and current federal prohibition, state-sanctioned medical cannabis laws each
have unique constructions.8 West Virginia’s Medical Cannabis Act is no
exception and was the subject of much debate and alteration prior to passage.9

1
Egill Karlsson, Russell “Rusty” Williams on Legalization of Medical Marijuana in West
Virginia, VIMEO (July 4, 2017), https://vimeo.com/224157914.
2
See Cheyann Shaw, I Tried Medical Cannabis During Chemo, and Here’s What Happened,
HEALTHLINE (Jan. 24, 2018), https://www.healthline.com/health/ovarian-cancer/medicalcannabis-helped-me-beat-cancer#1.
3
See Alexandra Gallo, The Foundation to Build a Proper Medical Cannabis Program in WV,
W. VA. CITIZEN ACTION GROUP (Jan. 15, 2018), https://wvcag.org/a-proper-medical-cannabisprogram-in-wv/.
4
Id.
5
See State Medical Marijuana Laws, NAT’L CONF. ST. LEGISLATURES (July 2, 2019),
http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
6
Justin McCarthy, Record-High Support for Legalizing Marijuana Use in U.S., GALLUP (Oct.
25, 2017), https://news.gallup.com/poll/221018/record-high-support-legalizing-marijuana.aspx.
7
8
9

See 21 U.S.C.A. § 812 (West 2018).
State Medical Marijuana Laws, supra note 5.

See Jake Zuckerman, Time Runs Out on Making Changes to WV’s Medical Cannabis
Program,
CHARLESTON
GAZETTE-MAIL
(Mar.
10,
2018),
https://www.wvgazettemail.com/news/legislative_session/time-runs-out-on-bill-making-changesto-wv-s/article_a1bbc4e8-eff5-5c0d-aef0-c5c852755ba9.html.
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This Note will argue that reducing unnecessary restrictions and allowing
medical cannabis in its dry leaf form will better serve patients by reducing
financial barriers erected by the Act’s strict regulations, thereby increasing
patient access. This Note will further argue that increasing patient access should
have additional social benefits such as boosting the economy while lessening the
prevalence of the cannabis black market. Part I will examine the broad cannabis
landscape including medical efficacy, brief history, and current policy and
economic considerations associated with the budding cannabis industry. Part II
will summarize the current provisions of West Virginia’s Medical Cannabis Act.
Part III will compare West Virginia’s medical cannabis law and policies with
those of other states that have comprehensive medical cannabis programs. Part
IV will conclude by arguing that dry leaf prohibition and other restrictions are
based on unfounded and outdated fears and that West Virginia patients and
residents alike will be better served by provisions allowing dry leaf dispersion,
which encourage a more robust medical market.
II. SUMMARY OF THE CURRENT AND HISTORICAL CANNABIS LANDSCAPE
Historically, cannabis was regarded as medicinal. Cannabis was used for
a variety of ailments in Ancient Egypt and appears in the oldest known Chinese
pharmacopeia.10 Cannabis was even recognized as a medicine in the United
States pharmacopeia in the 19th century.11 Cannabis did not gain its nefarious
reputation in the United States until early in the 20th century when it began to be
associated with Mexican immigrants and the Mexican Revolution, thus
encouraging the popularization of the term “marijuana.”12 Nationwide
prohibition soon followed.13
In the modern era, California led the way for state-sanctioned medical
cannabis programs in 1996 with a voter-approved ballot initiative that allowed
for medical cannabis use under state law.14 However, the initial program did not
have a state-licensing mechanism, which led to differential enforcement of the
laws and an unregulated “gray” market for medical cannabis.15 Colorado was the
first state to commercialize medical cannabis access in 2009 with the adoption
of a state-licensed dispensary system.16 Since then, research into the
effectiveness and potential negative consequences of using medical cannabis has
exploded, prompting the National Academies of Sciences, Engineering, and

10

STEVE DEANGELO, THE CANNABIS MANIFESTO: A NEW PARADIGM FOR WELLNESS 42 (2015).

11

Id. at 19.
Id. at 21.

12
13
14
15
16

See infra text accompanying note 71.
State Medical Marijuana Laws, supra note 5.
DEANGELO, supra note 10, at 93–94.
Id. at 105–07.
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Medicine to report on a review of over 10,000 scientific abstracts from marijuana
health research.17 Despite the significant pool of research examined in making
the report, the Academy has concluded that cannabis research requires additional
support and improvement, thanks in large part to the federal barriers impeding
research.18
A. Cannabis Has the Medical Potential to Mitigate the Effects of the Opioid
Crisis and Provide Treatment and Alternative Therapy for a Variety of
Ailments
Despite federal barriers to research, the cannabis plant’s medical
efficacy has been substantially supported by science. In the 1990s, thanks in part
to cannabis, scientists discovered a previously unknown cellular communication
network in the body called the endocannabinoid system.19 The endocannabinoid
system regulates other critical biological systems, including the “central nervous
system, the autonomic nervous system, the endocrine network, the immune
system, the gastrointestinal tract, the reproductive system, and
microcirculation.”20 Thus, “if properly activated, the [endocannabinoid system]
is capable of suppressing numerous cancers and may be protective against
Alzheimer’s disease.”21 The endocannabinoid system also “strengthens our
nervous and immune systems, initiates pain control, and calms inflammation.”22

17
See NAT’L ACADS. OF SCIS., ENG’G, & MED., THE HEALTH EFFECTS OF CANNABIS AND
CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH 4
(2017).
18
Id. at 395–401. Thanks to the federal prohibition of cannabis and the plant’s status as a
Schedule I drug, researchers face a myriad of regulatory, access, and funding barriers when
attempting to conduct cannabis research. Potential researchers must apply for the opportunity to
conduct cannabis research with the National Institute on Drug Abuse (“NIDA”), the U.S. Food and
Drug Administration (“FDA”), and the U.S. Drug Enforcement Administration (“DEA”). The
NIDA mission is to advance science on the causes and consequences of drug addiction, rather than
to investigate the therapeutic potential of a particular drug. The DEA imposes strict regulations
such as onsite security inspections and a mandate requiring as few employees handling the
cannabis as possible, in order to prevent cannabis diversion. Federal cannabis supplied for research
is sourced exclusively from the University of Mississippi and has historical been of lower potency
and quality than products available in state markets. Additionally, edibles and concentrates are not
typically available through federal sources. Id. at 377–93.
19
20

CLINT WERNER, MARIJUANA: GATEWAY TO HEALTH 13 (2011).
DEANGELO, supra note 10, at 45.

21
UWE BLESCHING, THE CANNABIS HEALTH INDEX: COMBINING THE SCIENCE OF MEDICAL
MARIJUANA WITH MINDFULNESS TECHNIQUES TO HEAL 100 CHRONIC SYMPTOMS AND DISEASES 1
(2015).
22
Id.
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The National Cancer Institute first reported that tetrahydrocannabinol
(“THC”)23 inhibits the growth of lung cancer tumors and increases bone marrow
resistance to cancer in 1975.24 Despite failed attempts by the National Institute
on Drug Abuse to fund studies finding a causal link between cannabis and cancer,
data continues to suggest that cannabis can be an effective treatment for
cancer-induced symptoms or cancer treatment–induced symptoms.25 More
controversially, some advocates claim that evidence suggests cannabis is capable
of fighting, preventing, and inhibiting the growth of various cancers.26 However,
even after its 1975 reporting, the National Cancer Institute remains conservative
in its messages on cannabis, stating simply that “[c]annabinoids may have
benefits in the treatment of cancer-related side effects,”27 but that “there is
insufficient evidence to recommend . . . [cannabis] as a treatment for
cancer-related symptoms . . . however, additional research is needed.”28
The cannabis plant’s medical potential does not end with cancer
treatment. There are also empirical indications that cannabis can be an effective
tool for preventing and treating opiate addiction.29 The nation’s opioid crisis has

23
“THC is the best known of the cannabinoids and is notorious for its psychoactive effects.”
However, it is not strictly used for recreational intoxication. THC has a wide range of potential
medical applications including providing patients with relief from insomnia, chronic pain,
cancer-related symptoms, and PTSD. DEANGELO, supra note 10, at 44.
24
Id. at 46.
25

Id. at 47.
Id. The author notes the reputable institutions providing the data which supports this claim,
including, “the University of Madrid, the British Journal of Cancer, the University of California
San Diego, the University of South Florida, and the National Cancer Institute.” The author
speculates that “[i]f any other substance showed the same results, hundreds of millions of dollars
in public funding would be devoted to developing it.” Id. at 48 (“It is beyond reason that our tax
dollars have for decades been poured into proving impossible myths about cannabis instead of
exploring the most promising treatment for cancer ever discovered.”). Anecdotes from
medical-cannabis consuming cancer patients supporting this claim are not difficult to find, but it
should be noted that anecdotes are not substitutes for data that is a product of rigorous scientific
method; for a local example, see Conor Griffith, Cannabis Legalization Encouraged During WV
Municipal
League
Conference,
MORGANTOWN
NEWS
(Aug.
9,
2018),
https://www.wvnews.com/morgantownnews/news/cannabis-legalization-encouraged-during-wvmunicipal-league-conference/article_0b2f8782-231b-500c-b11e-5298b0673ba1.html (featuring
an interview with a patient advocate representing the West Virginia Medical Cannabis Advisory
Board claiming that “in 2012 cancer tried to kill me and an illegal flower stopped that from
happening”).
27
Cannabis and Cannabinoids (PDQ)—Health Professional Version, NAT’L CANCER INST.,
https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq (last updated July 16, 2019)
[hereinafter Cannabis & Cannabinoids].
26

28
29

Id.
DEANGELO, supra note 10, at 53.
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become a commonly understood cultural fact and is responsible for more than
130 daily overdose deaths throughout the nation.30
THC was found to suppress “behavioral, biochemical, and molecular
dependence in morphine-addicted rats” by the Laboratory for Physiopathology
of Diseases of the Central Nervous System at Sorbonne University in 2009.31
Subsequent human-subject experiments conducted by Columbia University
found that “both heroin and cocaine addicts were more likely to adhere to their
treatment when they used cannabis.”32 One California physician reports
anecdotally that “[a]mazingly the effects of cannabinoids can reduce or eliminate
the majority of symptoms of opiate withdrawal. Cannabis can reduce anxiety and
agitation, improve sleep, and help normalize the digestive tract.”33
Early data from states that implemented cannabis reform policies
seemingly validated the positive impact cannabis has on opioid treatment and the
crisis in general.34 “Cannabis access is associated with reduced rates of opioid
use and abuse, opioid-related hospitalizations, opioid-related traffic fatalities,
opioid-related drug treatment admissions, and opioid-related overdose deaths.”35
These data have led commentators to suggest cannabis reform and access as a

30
Opioid Overdose Crisis, NAT’L INST. ON DRUG ABUSE, https://www.drugabuse.gov/drugsabuse/opioids/opioid-overdose-crisis (last updated Jan. 2019); see also Opioid Crisis Fast Facts,
CNN (Aug. 28, 2019, 4:15 PM), https://www.cnn.com/2017/09/18/health/opioid-crisis-fastfacts/index.html (highlighting the increase in rates of addiction and overdose across recent decades,
as well as the concurrent reactive increase in opioid regulation).
31
32

DEANGELO, supra note 10, at 53.
Id.

33

Id. at 54.
See Paul Armentano, Studies: Marijuana Legalization Associated with Reduced Opioid
Prescribing Trends, NORML BLOG (Apr. 2, 2018), https://blog.norml.org/2018/04/02/studiesmarijuana-legalization-associated-with-reduced-opioid-prescribing-trends/.
34

35
Relationship Between Marijuana and Opioids, NORML, https://norml.org/marijuana/factsheets/item/relationship-between-marijuana-and-opioids (last visited Sept. 9, 2019) (analyzing and
citing a collection of studies from various institutions including: the University of Alabama, the
Mental Health Clinician, Neuropsychopharmacology, Cannabis and Cannabinoid Research,
Substance Abuse and Misuse, and the European Journal of Internal Medicine). Unfortunately, more
recent studies have failed to replicate the promising early findings. See Chelsea L. Shover et al.,
Association Between Medical Cannabis Laws and Opioid Overdose Mortality Has Reversed Over
Time, PNAS (June 25, 2019), https://www.pnas.org/content/116/26/12624 (finding that the data
showing a negative association between medical cannabis laws and opioid overdose mortality from
1999 to 2010 has actually reversed, becoming a positive association through 2017). However,
causation cannot be equated to causation in either direction. The authors of the study “find it
unlikely that medical cannabis—used by about 2.5% of the U.S. population—has exerted large
conflicting effects on opioid overdose mortality. A more plausible interpretation is that this
association is spurious.” Id. (“Research into therapeutic potential of cannabis should continue, but
the claim that enacting medical cannabis laws will reduce opioid overdose death should be met
with skepticism.”). Thus, this appears to be another illustration of the deficiency in cannabis
research. See supra note 18 and accompanying text. Ultimately, as noted by the authors of the
Shover study, cannabis’s therapeutic potential should not be discounted by these findings alone.
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serious solution to the nation’s opioid crisis.36 However, cannabis reform
opponents often argue that cannabis will act as a “gateway” to more destructive
drugs37 or fear that cannabis access will simply encourage its use as an alternative
drug.38 Further, West Virginians who oppose progressive reform are concerned
about the addictive potential of cannabis, especially because pro-legalization
groups have argued for years that cannabis is non-addictive.39
However, these arguments are not well supported by our understanding
of drug abuse or the cannabis plant specifically. First, “[t]he Institute of
Medicine, itself a federal agency, [states]: ‘There is no evidence that marijuana
serves as a stepping stone to other drugs on the basis of its particular
physiological effect.’”40 Various studies have more recently supported this
proposition by finding that factors other than cannabis’s psychoactive effect
(such as personal predisposition, concurrent availability, and unemployment) are
stronger explanations for the proposed “gateway effect” of cannabis.41 Second, a
36
See Kendra Fershee, The Next Thousand-Year Flood: The Case for Federal Legalization of
Medical
Marijuana,
HUFFINGTON
POST
(Dec.
18,
2017,
3:45
PM),
https://www.huffingtonpost.com/entry/the-next-thousand-year-flood-the-case-forfederal_us_5a382860e4b0578d1beb71c1 (describing the devastating effects of the opioid crisis
and concluding that “there is one solution in particular that we West Virginians can embrace to
turn the ship . . . nationally legalized medical marijuana”); see also Sanjay Gupta, Dr. Sanjay
Gupta to Jeff Sessions: Medical Marijuana Could Save Many Addicted to Opioids, CNN, (Apr. 24,
2018, 8:25 AM), https://www.cnn.com/2018/04/24/health/medical-marijuana-opioid-epidemicsanjay-gupta/index.html (“Cannabis . . . show[s] potential to save lives in three important ways.
Cannabis can help treat pain, reducing the initial need for opioids . . . eas[e] opioid withdrawal
symptoms, . . . [and] the compounds found in cannabis can heal the diseased addict’s brain, helping
them break the cycle of addiction.”).
37
DEANGELO, supra note 10, at 52 (“Faced with overwhelming evidence that cannabis itself
is not addictive, prohibitionists . . . have advanced the gateway theory: that cannabis should remain
illegal because it leads to the use of addictive drugs like heroin.”).
38

While debating the West Virginia Medical Cannabis Act, Senator Mike Azinger voiced
concern that “the bill will take away from the ‘fear’ and ‘mystery’ of marijuana and will encourage
its use among the state’s youth.” See Jake Zuckerman, Time Runs Out on Bill Making Changes to
WV’s Medical Cannabis Program, CHARLESTON GAZETTE-MAIL (Mar. 10, 2018),
https://www.wvgazettemail.com/news/legislative_session/time-runs-out-on-bill-making-changesto-wv-s/article_a1bbc4e8-eff5-5c0d-aef0-c5c852755ba9.html (“We’re saying as a culture this is
not a dangerous drug and what we’re doing is fine . . . . We know intuitively there is something to
be afraid of.”).
39

Erin Beck, Marijuana Arrests Make Up Majority of Drug Crimes, CHARLESTON GAZETTEMAIL (Sept. 1, 2014), https://www.wvgazettemail.com/news/marijuana-arrests-make-up-majorityof-drug-crimes/article_42c24b21-2b5d-5aca-b678-70493b3aba9e.html (then-Charleston Police
Bureau Chief of Investigative Services voicing concerns about the addictive potential of cannabis
while referring to a Colorado doctor’s increase in marijuana addiction treatment after medical
access was commercialized in 2009).
40
DEANGELO, supra note 10, at 53 (quoting DIV. OF NEUROSCIENCE & BEHAV. HEALTH, INST.
OF MED., MARIJUANA AND MEDICINE: ASSESSING THE SCIENCE BASE (Janet E. Joy et al. eds., 1999)).
41
See Ralph E. Tarter et al., Predictors of Marijuana Use in Adolescents Before and After
Licit Drug Use: Examination of the Gateway Hypothesis, 163 AM. J. PSYCHIATRY 2134 (2006),
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fear of replacing one drug (opioids) with another (cannabis) simply ignores the
fact that each drug is unique, and thus a drug’s use should be assessed on the
basis of its potential to heal and potential to harm. While cannabis’s addictive
potential has been subject to hyperbole on both sides of the argument throughout
its prohibition in the United States, it appears that the truth lies somewhere in the
middle.42 Cannabis use can certainly escalate to a point that reaches a substance
abuse disorder and disrupts an individual’s life significantly, as recognized by
the Diagnostic and Statistical Manual of Mental Disorders43 (“DSM”), but the
chemical dependency and withdrawal effects are far less severe than that of most
other drugs.44 Further, contemporary discussion on addiction strongly suggests
that environmental factors are more predictive of developing addiction and have
a greater impact on treatment than access to drugs or the chemical makeup of the
drugs themselves.45

https://ajp.psychiatryonline.org/doi/abs/10.1176/ajp.2006.163.12.2134; Andrew R. Morral et al.,
Using Marijuana May Not Raise the Risk of Using Harder Drugs, RAND DRUG POL’Y RES. CTR.
(2002), https://www.rand.org/pubs/research_briefs/RB6010.html.
42
For a brief discussion on cannabis addiction and history, see Hal Arkowitz & Scott O.
Lilienfeld, Experts Tell the Truth About Pot, SCI. AM. (Mar. 1, 2012),
https://www.scientificamerican.com/article/the-truth-about-pot/.
AM. PSYCHIATRIC ASS’N, DIAGNOSTIC
509 (5th ed. 2013).
43

44

AND

STATISTICAL MANUAL

OF

MENTAL DISORDERS

See Cannabis & Cannabinoids, supra note 27 (“Although cannabinoids are considered by
some to be addictive drugs, their addictive potential is considerably lower than that of other
prescribed agents or substances of abuse . . . . Withdrawal symptoms . . . appear to be mild
compared with withdrawal symptoms associated with opiates or benzodiazepines, and the
symptoms usually dissipate after a few days.”).
45
For a detailed discussion on the role environmental factors (such as trauma, poverty, or
isolation) play in developing addiction, see GABOR MATÉ, IN THE REALM OF HUNGRY GHOSTS:
CLOSE ENCOUNTERS WITH ADDICTION (2010) (arguing that access to drugs alone does not cause
addiction and that the three necessary factors for substance addiction to occur are (1) a susceptible
organism (trauma histories are strong addiction predictors), (2) a drug with addictive potential
(including cannabis), and (3) environmental stress); Making Sense: #142-Addiction, Depression,
and a Meaningful Life: A Conversation with Johann Hari, SAM HARRIS (Nov. 12, 2018),
https://samharris.org/podcasts/142-addiction-depression-meaningful-life/. Notably both sources
discuss the 1980 “rat park” experiment in which researchers attempted to create a kind of utopia
for the rat subjects. The rats were housed in an environment 200 times the square footage of a
standard laboratory cage, complete with physical and social enrichment through “toys” and access
to other rats of both sexes. The park also contained a tunnel large enough to accommodate only
one rat with a morphine dispenser at its end. Even after dissolving morphine into a sweet liquid
that is otherwise irresistible to rats and forcibly exposing the rats to morphine to develop a chemical
dependence, rats in the park consistently avoided the morphine when given a choice. By contrast,
socially isolated rats in standard laboratory cages consumed up to 20 times more morphine than
their “rat park” counterparts. MATÉ, supra, at 145–46 (citing Bruce K. Alexander et al., Effect of
Early and Later Colony Housing on Oral Ingestion of Morphine in Rats, 15 PHARMACOLOGY
BIOCHEMISTRY & BEHAV. 571 (1981), https://doi.org/10.1016/0091-3057(81)90211-2).
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B. State-Level Cannabis Reform Brings Significant Economic Impact with
Only Minor Side Effects
Public debate, attention, and support regarding medical and recreational
cannabis have also increased dramatically. According to Gallup, 66% of
Americans now support full recreational cannabis legalization, “mark[ing] the
third consecutive year that support on the measure has increased and established
a new record.”46 This is up from just 34% in 2002.47 Further, the current support
is bipartisan with 72% support from Democrats, 67% support from independents,
and 51% support from Republicans.48 Other studies have found national public
support in favor of medical cannabis legalization as high as 93%.49 In West
Virginia, public support for medical cannabis is at 63%, with only 34% of West
Virginia voters currently supporting legalizing recreational cannabis.50 Support
for both medical and recreational cannabis in West Virginia appears to be rising
with medical use support seeing a six-point increase and recreational use support
seeing a 12-point increase when compared to a similar poll conducted a year
prior.51
Colorado and Washington made history by legalizing recreational adult
use of cannabis in 2012.52 California, Oregon, Alaska, Nevada, Massachusetts,
Maine, Vermont, Michigan, Illinois, and the District of Colombia have followed
suit and legalized recreational adult use.53 Currently 33 states have
comprehensive medical cannabis programs.54 As a result, the legal cannabis

46

Justin McCarthy, Two in Three Americans Now Support Legalizing Marijuana, GALLUP
(Oct. 22, 2018), https://news.gallup.com/poll/243908/two-three-americans-support-legalizingmarijuana.aspx.
47
Id.
48

Id.
Press Release, Quinnipiac Univ. Poll, U.S. Voters Believe Comey More than Trump,
Quinnipiac Univ. Poll Finds; Support for Marijuana Hits New High (Apr. 26, 2018),
https://poll.qu.edu/images/polling/us/us04262018_ufcq23.pdf/.
49

50

Wendy Holdren, Poll Reveals West Virginia Opinion on Politics, Opioids and More, REG.HERALD (Beckley, W. Va.) (Jan. 21, 2018), http://www.register-herald.com/health/poll-revealswest-virginia-opinion-on-politics-opioids-and-more/article_64fb9424-fd50-11e7-a5aea3e364781757.html.
51
52
53

Id.
State Medical Marijuana Laws, supra note 5.

Id. In 2019, Illinois became the first state to legalize cannabis possession and sales
legislatively. Most other reforms have come through ballot initiatives. See Amber Phillips, How
Illinois Became the First State Legislature to Legalize Marijuana Sales, WASH. POST (June 4,
2019),
https://www.washingtonpost.com/politics/2019/06/04/how-illinois-became-first-statelegislature-legalize-marijuana-sales/.
54
State Medical Marijuana Laws, supra note 5 (even states with comprehensive medical use
programs vary widely on regulations pertaining to dispensaries, acceptable forms of cannabis, and
qualifying medical conditions).
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industry has grown tremendously, with consumers spending $5.9 billion on legal
cannabis in the United States in 2016.55 By 2021, that figure is expected to reach
$19 billion.56 In Colorado alone, consumers have spent approximately $6.8
billion in total cannabis (medical and recreational) sales to date,57 leading to over
$1 billion in state tax revenue through 2019.58
Because Colorado was one of the first states to embrace legal,
commercialized recreational cannabis, its model has been the subject of much
scrutiny as to its impacts on various aspects of society. One study found that as
of October 2016, the legal cannabis industry in Colorado was responsible for
creating 18,005 new full-time-equivalent positions and that “[b]ecause the
industry is wholly confined within Colorado, spending on marijuana creates
more output and employment per dollar spent than 90 percent of Colorado
industries.”59 Colorado State University–Pueblo’s Institute of Cannabis Research
found that the regulated and taxed industry led to a net positive impact of more
than $35 million in Pueblo County’s local economy alone.60
Naturally, state-sanctioned access to cannabis has raised traffic safety
concerns.61 Legalization opponents point to rising numbers of automobile
accidents, as well as an increase in THC-positive drivers involved in fatal
crashes, to highlight the potential dangers associated with increased cannabis
access.62 Proponents and cannabis industry analysts claim the increase in total
accidents can be attributed simply to an increase in population, and that the
increase in THC-positive drivers does not determinatively indicate impairment

55
Avantika Chilkoti, States Keep Saying Yes to Marijuana Use. Now Comes the Federal No.,
N.Y. TIMES (July 15, 2017), https://www.nytimes.com/2017/07/15/us/politics/marijuana-lawsstate-federal.html.
56
Id.
57
Marijuana
Sales
Reports,
COLO.
DEP’T
REVENUE,
https://www.colorado.gov/pacific/revenue/colorado-marijuana-sales-reports (last updated Aug.
2019).
58
Marijuana
Tax
Data,
COLO.
DEP’T
REVENUE,
https://www.colorado.gov/pacific/revenue/colorado-marijuana-tax-data (last updated Aug. 2019).
59
Miles Light et. al., The Economic Impact of Marijuana Legalization in Colorado,
MARIJUANA
POL’Y
GROUP
(Oct.
2016),
http://mjpolicygroup.com/pubs/MPG%20Impact%20of%20Marijuana%20on%20ColoradoFinal.pdf.
60
Mona Zhang, Legal Marijuana Is a Boon to the Economy, Finds Study, FORBES (Mar. 13,
2018, 5:34 PM), https://www.forbes.com/sites/monazhang/2018/03/13/legal-marijuana-is-a-boonto-the-economy-finds-study/#39aa9e7dee9d.

See Drugged Driving: The Cannabis Conversation, COLO. DEP’T TRANSP.,
https://www.codot.gov/safety/alcohol-and-impaired-driving/druggeddriving (last visited Sept. 8,
2019).
62
David Migoya, Exclusive: Traffic Fatalities Linked to Marijuana Are Up Sharply in
Colorado. Is Legalization to Blame?, DENV. POST (Aug. 25, 2017, 10:01 AM),
https://www.denverpost.com/2017/08/25/colorado-marijuana-traffic-fatalities/.
61
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because, unlike alcohol, THC in the blood does not necessarily directly correlate
with THC-caused impairment.63 The National Highway Traffic Safety
Administration report to Congress illustrates the complexities in regulating
cannabis-impaired driving because of how differently the body reacts to and
processes cannabis when compared to alcohol.64 Fatalities per mile driven, often
a lesser-reported number, sheds some light on the debate—1.03 fatalities per 100
million vehicle miles traveled in Colorado only rose to 1.17 vehicle fatalities
between 2013 and 2016 as the national rate rose from 1.1 to 1.19 during the same
period.65
Another significant concern related to cannabis reform, either through
recreational or medical laws, is its potential for increasing teenage use. And
rightfully so, given most data conclusively finds that cannabis use negatively
impacts cognitive development in the teenage brain.66 Two of the most

63
Id. (“Unlike alcohol, THC can remain detectable in the blood stream for days or weeks,
when any impairment wears off in a matter of hours . . . [s]o all those number[s] really tell us is
that . . . a larger number of people are consuming cannabis and then, at some point . . . (are) driving
a car.”).
64
RICHARD P. COMPTON, NAT’L HIGHWAY TRAFFIC SAFETY ADMIN., MARIJUANA-IMPAIRED
DRIVING:
A
REPORT
TO
CONGRESS
5–7
(2017),
https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/documents/812440-marijuana-impaired-drivingreport-to-congress.pdf (noting that in contrast to alcohol impairment’s positive correlation with
BAC, marijuana impairment is not significantly correlated with blood THC levels, leading to
difficulties in policing impaired driving). Notably, the administration reported conclusively that
marijuana consumption significantly affected psychomotor and cognitive skills necessary for
driving. Id. at 11. However, the NHTSA’s “Crash Risk” Study, which is the first large-scale case
control crash risk study in the United States to include drugs other than alcohol, found that drivers
testing positive for THC did not have a statistically significant increased risk of crash involvement
when compared to the sober control group after adjusting for demographic variables such as age,
gender, and race or ethnicity. Id. at 26. When unadjusted for demographic variables, the THC
positive group saw a 25% increase in crash risk. Id. at 25. By comparison, “drivers with a [breath
alcohol concentration (“BrAC”)] of 0.05 are approximately [two] times more likely to crash than
drivers at zero BrAC. At 0.08 BrAC, the adjusted relative risk of crashing is approximately four
times that of drivers at zero BrAC.” Richard. P. Compton & Amy Berning, Traffic Safety Facts
Research Note: Drug and Alcohol Crash Risk, NAT’L HIGHWAY TRAFFIC SAFETY ADMIN. (Feb.
2015), http://www.nhtsa.gov/staticfiles/nti/pdf/812117-Drug_and_Alcohol_Crash_Risk.pdf.
65
See NAT’L HIGHWAY TRAFFIC SAFETY ADMIN., FATALITY RATES: COLORADO, U.S. AND BEST
STATE (2017), https://cdan.nhtsa.gov/STSI.htm# (click on Colorado). It should be noted that the
proliferation of smart phones and a national increase in distracted driving present a potentially
substantial confounding variable when attempting to examine accident increases attributable to
cannabis access. See Kurt Meisinger & Scott A. Rushing, Fatal Distraction: Smartphones and
Recent Increases in US Motor Vehicle Fatalities, 33 ON RISK 42, 49 (2017),
https://www.rgare.com/docs/default-source/newsletters-articles/driverrisk.pdf?sfvrsn=7ea788_0.
66

Université de Montréal, Teen Cannabis Use Is Not Without Risk to Cognitive Development,
SCIENCEDAILY
(Oct.
3,
2018),
https://www.sciencedaily.com/releases/2018/10/181003090325.htm (citing Jean-François G.
Morin et al., A Population-Based Analysis of the Relationship Between Substance Use and
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significant predictors for teen use are access and perception of risk. While
legalization may reduce teenage access by restricting the black market, it also
tends to reduce the public’s perception of harm. Thus, legalization could both
positively and negatively impact significant factors for predicting teen use.
Consequently, reports on the effects of teenage consumption related to specific
policy changes have varied widely.67 However, the National Institute on Drug
Abuse reports that national cannabis “use declined among 8th graders and
remains unchanged among 10th and 12th graders compared to five years ago,
despite the changing state marijuana laws during this time period.”68 California
also reported significant declines in teen consumption from 2015–2017, just as
the state was on the verge of recreational legalization.69
Unfortunately, Colorado’s crime rate has also been on an upward trend
since the recreational market was established in 2014.70 This trend is divergent
from the descending national crime rate, leading to substantial debate as to the
cause of the increase.71 However, when analyzing the relationship between
state-sanctioned cannabis and crime, it is imperative to remember that correlation
is not causation. Accordingly, a local sheriff attributes increases in local wealth
and transient populations that are associated with cannabis as the connection
between cannabis and crime.72 Notably, property crime is reported as the driver
of the increase.73 Further, it is also important to remember that the federal

Adolescent
Cognitive
Development,
176
AM.
J.
PSYCHIATRY
98
(2019),
https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2018.18020202).
67
See German Lopez, The Research Suggests Marijuana Legalization Could Lead to More
Use, VOX (Nov. 14, 2018), https://www.vox.com/identities/2018/8/20/17938388/marijuanalegalization-more-use (reporting three varying studies, one finding medical cannabis laws
increasing teen dependence and not overall use, another finding medical cannabis laws increasing
overall use for teens and adults, and the last finding no increase in teenage consumption after
legalizing medical cannabis).
68
Monitoring the Future Survey: High School and Youth Trends, NAT’L INST. ON DRUG
ABUSE,
https://www.drugabuse.gov/publications/drugfacts/monitoring-future-survey-highschool-youth-trends (last updated Dec. 2018).
69

GREGORY AUSTIN ET AL., SCHOOL CLIMATE, SUBSTANCE USE, AND STUDENT WELL-BEING IN
CALIFORNIA 2015–17 (2018), https://data.calschls.org/resources/Biennial_State_1517.pdf.
70

See Scott McLean & Sara Weisfeldt, Colorado Governor Won’t Rule Out Banning
Marijuana
Again.
Here’s
Why,
CNN
(Apr.
20,
2018)
https://www.cnn.com/2018/04/20/us/colorado-marijuana-and-crime/index.html.
71
Id.
72

Id.
Id. This logically supports the local sheriff’s assertion that increases in local wealth and
transient population are responsible for the increase in crime. It should be further noted that while
the rate of cannabis consumption has increased nationally since the 1990s, the rate of violent crime
has concurrently decreased. See Crime in the United States by Volume and Rate per 100,000
Inhabitants, 1998–2017, FED. BUREAU INVESTIGATION (2017), https://ucr.fbi.gov/crime-in-theu.s/2017/crime-in-the-u.s.-2017/tables/table-1; Nationwide Trends, NAT’L INST. ON DRUG ABUSE,
https://www.drugabuse.gov/publications/drugfacts/nationwide-trends (last updated June 2015).
73
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cannabis prohibition and banking restrictions encourage cash transactions and
onsite cash vaults for state-legal cannabis organizations,74 thereby increasing
property crime risk factors in legal states.
Cannabis reform is not strictly limited to the United States. Currently
two countries, Uruguay75 and Canada,76 have legalized recreational cannabis
subject to differing regulations. Two more countries, South Africa77 and
Mexico,78 have seen recent supreme court rulings holding that total cannabis
prohibition is unconstitutional. Many more have legalized medical cannabis in
varying forms.79
C. Federal Cannabis Prohibition Creates Unnecessary Uncertainty for
State Reform Efforts
Although near absolute federal prohibition remains in effect, this has not
always been the case. Cannabis possession and use was legal in the United States
until national policy began to shift with the passage of the Marihuana Tax Act in
1937.80 There is some historical debate as to the policy considerations that
motivated the 75th Congress to prohibit cannabis. Those considerations range
from racism81 and classism to a mistake on the part of the legislators as to a

“The rift between federal and state law has left banks trapped between their mission to serve
the financial needs of their local communities and the threat of federal law enforcement action.”
Cannabis: Bridging the Gap Between State and Federal Law, AM. BANKERS ASS’N,
https://www.aba.com/advocacy/our-issues/cannabis (last visited Sept. 8, 2019).
74

75
See Malena Castaldi & Felipe Llambias, Uruguay Becomes First Country to Legalize
Marijuana Trade, REUTERS (Dec. 10, 2013, 7:43 PM), https://www.reuters.com/article/usuruguay-marijuana-vote/uruguay-becomes-first-country-to-legalize-marijuana-tradeidUSBRE9BA01520131211 (observing the legislative end to prohibition in Uruguay which allows
purchase by Uruguay residents only).
76
Kate Rogers, Eyes of the Global Marijuana Industry Are on Canada as It Legalizes
Recreational Use, CNBC (Sept. 24, 2018, 2:09 PM), https://www.cnbc.com/2018/09/24/eyes-ofthe-global-marijuana-industry-are-on-canada-as-it-legalizes-recreational-use.html.
77

Casey Quackenbush, South Africa’s Supreme Court Has Legalized the Private Use of
Marijuana, TIME (Sept. 19, 2018), http://time.com/5400271/south-africa-legalizes-marijuanacannabis/ (“South Africa’s top court unanimously legalized the private use of cannabis on Tuesday,
upholding a lower court’s decision ruling that it was ‘unconstitutional and therefore invalid’ to
criminalize the drug . . . .”).
78
German Lopez, Mexico Just Took a Big Step Toward Marijuana Legalization, VOX (Nov.
1, 2018, 11:50 AM), https://www.vox.com/world/2018/11/1/18051592/mexico-marijuanalegalization-supreme-court.
79
Sean Williams, These 30 Countries Have Legalized Medical Marijuana in Some Capacity,
MOTLEY FOOL (July 21, 2018, 11:41 AM), https://www.fool.com/investing/2018/07/21/these-30countries-have-legalized-medical-marijuan.aspx.
80
See Becky Little, Why the U.S. Made Marijuana Illegal, HIST. (Aug. 4, 2017),
https://www.history.com/news/why-the-u-s-made-marijuana-illegal.
81
Id.
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perceived (but nonexistent) difference between “marijuana” and “cannabis.”82
Regardless, sound policy considerations appear to have been absent from the
initial national prohibition effort.
Increased drug use during the 1960s led to a more aggressive national
prohibition effort.83 In 1970, Congress passed the Controlled Substances Act
(“CSA”), which adopted harsher penalties for possession and cultivation of
cannabis.84 Despite a 1972 report made by the National Commission on
Marijuana and Drug Abuse that recommended decriminalization of simple
cannabis possession,85 the strict prohibitions of the CSA have continued into the
present. The Nixon Administration aggressively refused to consider any of the
Commission’s recommendations in regard to cannabis.86
Federal prohibition enforcement has become increasingly complex and
uncertain as states continue to adopt more progressive policies, especially given
the administrative changes following the 2016 election. In 2013, under the
Obama Administration, Deputy Attorney General James M. Cole released a
memorandum to U.S. Attorneys regarding enforcement of the federal cannabis
prohibition (the “Cole Memo”).87 The Cole Memo encouraged prosecutors to
take a hands-off approach in jurisdictions with robust medical cannabis
regulatory schemes.88 In fact, it went as far as to claim “a robust system may
affirmatively address [federal marijuana priorities] by . . . implementing
effective measures to prevent diversion of marijuana outside of the regulated
system . . . and replacing an illicit marijuana trade that funds criminal enterprises

82

See DAVID R. FORD, MARIJUANA: NOT GUILTY AS CHARGED 64 (1997).
President Richard Nixon, Special Message to the Congress on Control of Narcotics and
Dangerous Drugs (July 14, 1969), https://www.presidency.ucsb.edu/node/239611.
84
21 U.S.C.A. § 841 (West 2018).
83

NAT’L COMM’N ON MARIHUANA & DRUG ABUSE, MARIHUANA: A SIGNAL OF
MISUNDERSTANDING (1972), http://www.druglibrary.org/schaffer/Library/studies/nc/ncmenu.htm
(“[T]he criminal law is too harsh a tool to apply to personal possession even in the effort to
discourage use. It implies an overwhelming indictment of the behavior which we believe is not
appropriate. The actual and potential harm of use of the drug is not great enough to justify intrusion
by the criminal law into private behavior, a step which our society takes only the greatest
reluctance.”).
86
See Gene Weingarten, Just What Was He Smoking?, WASH. POST (Mar. 21, 2002),
https://www.washingtonpost.com/archive/lifestyle/2002/03/21/just-what-was-hesmoking/e984a758-94fc-482f-a9d7-890c30a41b5e/?noredirect=on&utm_term=.f828f8946a09.
85

87

Memorandum from James M. Cole, Deputy Att’y Gen., for All U.S. Att’ys on Guidance
Regarding
Marijuana
Enforcement
(Aug.
29,
2013),
https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf [hereinafter Cole
Memo]. Notably, the Cole Memo was released prior to the 2014 elections in which Colorado and
Oregon legalized recreational use. However, the Cole Memo remained in effect during the budding
of the regulated recreational market until it was rescinded by Attorney General Jeff Sessions in
2018. See infra text accompanying note 125.
88
Cole Memo, supra note 87.
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with a tightly regulated market.”89 However, in 2018, under the Trump
Administration, Attorney General Jeff Sessions signed a memo rescinding the
Cole Memo.90 The new guidance directs U.S. Attorneys to “follow the
well-established principles that govern all federal prosecutions” when deciding
which “marijuana activities to prosecute.”91 Predictably, the new direction to
prosecutors prompted diverse commentary from legal analysts, scholars, and the
cannabis industry.92
A hemp93 farm in Mason County, West Virginia, provides a local
illustration of the complexities of the federal and state cannabis law scheme.
Prior to the recent passage of the Farm Bill, the U.S. Attorney for the Southern
District of West Virginia filed suit against the hemp farm, alleging violations of
the federal Controlled Substances Act due to the process by which the farm
obtained seeds as well as intent to sell processed hemp across state lines.94 The
defendant is licensed to grow hemp under the industrial hemp pilot program in

89
Id. The federal marijuana priorities also include: preventing distribution to minors,
preventing state-authorized marijuana activity from being used as a cover or pretext for the
trafficking of other illegal drugs or activity, preventing violence and the use of firearms in the
cultivation and distribution of marijuana, and preventing the exacerbation of other adverse public
health consequences associated with marijuana use. Id.
90
See Laura Jarrett, Sessions Nixes Obama-Era Rules Leaving States Alone that Legalize Pot,
CNN (Jan. 4, 2018, 5:44 PM), https://www.cnn.com/2018/01/04/politics/jeff-sessions-colememo/index.html.
91
Memorandum from Jefferson B. Sessions, III, Att’y Gen., for All U.S. Att’ys on Marijuana
Enforcement (Jan. 4, 2018), https://www.justice.gov/opa/press-release/file/1022196/download.
92
See Brad Auerbach, How Cannabis Entrepreneurs Feel About the Sessions’ Reversal of the
Cole
Memo,
FORBES
(Mar.
3,
2018,
7:32
PM),
https://www.forbes.com/sites/bradauerbach/2018/03/03/how-cannabis-entrepreneurs-feel-aboutsessions-reversal-of-the-cole-memo/#6ce92565c4ae (“Many observers across the political
spectrum concur that the decision will heighten uncertainty in an industry seeking stability.”); Ilya
Somin, Jeff Sessions Escalates the Federal War on Marijuana—and His Assault on Federalism,
VOLOKH CONSPIRACY (Jan. 4, 2018, 9:40 PM), http://reason.com/volokh/2018/01/04/jeff-sessionsescalates-federal-war-on-m (noting that rescission’s “impact may be relatively minor,” but calling
it an “assault on constitutional federalism” with the potential to “have a major chilling effect” if
even a small number of sellers are targeted); Jacob Sullum, Did Jeff Sessions’ Marijuana Memo
Restore
the
Rule
of
Law?,
REASON
(Jan.
5,
2018,
3:15
PM),
http://reason.com/blog/2018/01/05/did-jeff-sessions-marijuana-memo-restore (arguing that the
rescission could be an appropriate response to excessive exercising of power by the Obama
Administration).
93
Hemp is a low-THC (less than one percent) variety of the cannabis plant. “Industrial hemp
could be used in more than 25,000 products spanning nine markets, including agriculture, textiles,
recycling, automotive, furniture, food/nutrition/beverages, paper, construction materials, and
personal care . . . .” S. Con. Res. 32, 83d Leg., Reg. Sess. (W. Va. 2018) (emphasizing the
economic importance of industrial hemp, but recognizing that Congress has “failed to amend the
Controlled Substances Act to make clear that hemp . . . is not a controlled substance”).
94
See United States v. Mallory, 372 F. Supp. 3d 377, 379 (S.D. W. Va. 2019).
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West Virginia.95 Nevertheless, the court ordered a preliminary injunction
prohibiting the transportation or sale of any processed plant but allowing the farm
to harvest, dry, and process its crop.96 After the passage of the Farm Bill, the
court dissolved the preliminary injunction despite the government’s last-minute
attempt to question whether the crop at issue was in fact industrial hemp.97 West
Virginia Commissioner of Agriculture Kent Leonhardt expressed that his office
was “confused on why the U.S. Attorney’s Office is working so diligently to
thwart a growing agricultural industry in the state . . . [e]specially . . . when there
are so many other serious issues affecting West Virginia.”98
It seems worth noting the speed with which changes in the legal cannabis
landscape are taking place. Since early fall 2018, national public support for
cannabis increased by two percent;99 former Attorney General Sessions was
removed from his position by President Trump;100 the federal prohibition on
hemp was lifted via the Farm Bill;101 and the Joint Economic Committee
Democrats issued a report on the national cannabis economy, which advocates
changing federal law so that states can experience the economic, medical, and
social justice benefits of cannabis reform without federal interference.102
Internationally, Canada’s nationwide legalization went into effect, and South
Africa’s Supreme Court struck down blanket prohibition of personal cannabis
use.

95
96

Id.
Id. at 379–80.

97

United States v. Mallory, No. 3:18-1289, 2019 U.S. Dist. LEXIS 10796, at *4 (S.D. W. Va.
Jan. 23, 2019) (“If the United States truly believed the product exceeded the THC limits, it could
have moved the Court to require testing long before now. Instead, the United States waited until
the CAMO Defendants will face certain harm by continuing the injunction before it requested
testing.”).
98
Correction: BC-WV—Hemp Farm-Lawsuit Story, U.S. NEWS & WORLD REP. (Sept. 26,
2018, 4:59 PM), https://www.usnews.com/news/best-states/west-virginia/articles/2018-09-24/usattorney-sues-west-virginia-hemp-farm.
99
Compare McCarthy, supra note 6 (reporting 64% public support), with McCarthy, supra
note 46 (reporting 66% public support).
100
Peter Baker et al., Jeff Sessions Is Forced Out as Attorney General as Trump Installs
Loyalist, N.Y. TIMES (Nov. 7, 2018), https://www.nytimes.com/2018/11/07/us/politics/sessionsresigns.html.
101
Andre Bourque, How Hemp and the Farm Bill May Change Life as You Know It, FORBES
(Dec. 17, 2018, 9:39 AM), https://www.forbes.com/sites/andrebourque/2018/12/17/how-hempand-the-farm-bill-may-change-life-as-you-know-it/#31204f00694c.
102

JOINT ECON. COMM. DEMOCRATS, THE NATIONAL CANNABIS ECONOMY (2018),
https://www.jec.senate.gov/public/_cache/files/bf473de9-98bb-4465-a310de992926409a/national-cannabis-economy-final.pdf (advocating the bipartisan STATES Act,
which would amend the Controlled Substances Act so that it would no longer apply to statesanctioned cannabis industries and clarify that financial transactions with state-legal cannabis
businesses are not drug trafficking).
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D. West Virginia Policy Considerations Illuminate the Potential for
Medical Cannabis to Benefit the State
The local effects of the opioid crisis are likely one of those “other serious
issues affecting West Virginia” present among Commissioner Leonhardt’s
concerns. West Virginia communities have been hit especially hard by the opioid
crisis.103 “In 2017, there were 833 drug overdose deaths involving opioids in
West Virginia—a rate of 49.6 deaths per 100,000 persons. This is the double the
rate in 2010 and threefold higher than the national rate of 14.6 deaths per 100,000
persons.”104 Tragically, overdoses are only one of many impacts on the state due
to the opioid crisis. Increased prevalence in injection drug use has also led to
increased prevalence of associated diseases.105 The combined costs related to
“fatalities, health care spending, addiction treatment, criminal justice and lost
productivity” are estimated to have cost the state a staggering $8.72 billion in
2016 alone.106 The lost productivity caused by the opioid crisis contributes to
West Virginia’s very poor labor force participation rate, which as of 2016 was
the lowest among all states at 53%.107 Not only is the participation rate poor, the
labor pool is also gradually shrinking as West Virginia is impacted by population
decline due to death rates exceeding birth rates coupled with an exodus from the
state.108
General health and wellness throughout the state is another significant
contributing factor to West Virginia’s labor force participation rate.109 According
to America’s Health Rankings annual 2018 report, West Virginia ranks 44th
among the states with respect to state health scores.110 West Virginia’s cancer

West
Virginia
Opioid
Summary,
NAT’L
INST.
ON
DRUG
ABUSE,
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state/west-virginiaopioid-summary (last updated Mar. 2019).
104
Id.
103

105

Id. (reporting prevalence of HIV and hepatitis C); see also Dina Fine Maron, West Virginia
Roiled by Side Effect of Opioid Crisis—A Major Hepatitis A Outbreak, SCI. AM. (Aug. 27, 2018),
https://www.scientificamerican.com/article/west-virginia-roiled-by-side-effect-of-opioid-crisis-amajor-hepatitis-a-outbreak/.
106

Wendy Holdren, Analysis Shows Opioid Crisis Cost West Virginia More than $8.72 Billion
in 2016, REG.-HERALD (Beckley, W. Va.) (May 4, 2018), https://www.registerherald.com/health/analysis-shows-opioid-crisis-cost-west-virginia-more-thanbillion/article_1db033ff-73c2-5a87-a267-18b58cc41101.html.
107
BUREAU OF BUS. & ECON. RESEARCH, W. VA. UNIV., WEST VIRGINIA ECONOMIC OUTLOOK
2018–2022,
at
1
(2017),
https://researchrepository.wvu.edu/cgi/viewcontent.cgi?article=1003&context=bureau_be.
108
Id. at 17.
109

Id. at 17–18.
AM.’S HEALTH RANKINGS, ANNUAL REPORT 2018, at 19 (2018). State health scores are
determined by examining 27 health indicators grouped into two categories: determinants of health
and health outcomes.
110
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incidence rate is above the national average,111 and research suggests that cancer
mortality rates are disproportionately higher within rural Appalachia (including
West Virginia) than the rest of the country.112 Sadly, these factors and many
others have resulted in West Virginia’s consistent status as one of the poorest
states in the country, with consistently low income and high levels of poverty.113
To combat this fact, the West Virginia Center on Budget and Policy recommends
increasing workforce participation (noting that criminal justice reform could
alleviate criminal histories that are currently a significant barrier to
employment), the general health of the workforce, and education and skills of
the workforce (advocating for a public teacher pay raise114).115
New FBI reporting procedures under the Trump Administration have
made specifically tracking cannabis arrests more difficult,116 but investigative
reporting reveals that cannabis arrests across the nation are increasing despite
legalization and reform efforts.117 In 2012, 53% of drug arrests in West Virginia
were for marijuana, most of which were simple possession.118 Given that the

111
State Cancer Profiles, NAT’L CANCER INST., https://statecancerprofiles.cancer.gov/quickprofiles/index.php?statename=westvirginia#t=2 (last visited Sept. 8, 2019).
112
Nengliang Yao et al., Cancer Disparities in Rural Appalachia: Incidence, Early Detection,
and
Survivorship,
33
J.
RURAL
HEALTH
375,
375
(2018),
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jrh.12213.
113
See W. VA. CTR. ON BUDGET & POLICY & AM. FRIENDS SERV. COMM., 2016 THE STATE OF
WORKING WEST VIRGINIA: WHY IS WEST VIRGINIA SO POOR? 1 (2016), https://wvpolicy.org/wpcontent/uploads/2018/5/SWWV-2016-release.pdf [hereinafter WORKING WEST VIRGINIA].
114

In February 2018, the entire state of West Virginia experienced a public-teacher strike that
made national news headlines. The strike was a response to a raise that teachers felt was insufficient
to cover cost-of-living increases, as well as concerns related to public-employee insurance
programs, health-care costs, and payroll-tax deduction options. The state superintendent of schools
said that he recognized teachers “deserve more,” but “the economic realities of our state may not
allow everything teachers deserve to take place immediately.” Emily Stewart, All of West
Virginia’s Teachers Have Been on Strike for Over a Week, VOX (Mar. 4, 2018),
https://www.vox.com/policy-and-politics/2018/3/3/17074824/west-virginia-teachers-strikejustice-union.
115
See WORKING WEST VIRGINIA, supra note 113.
116
Tom Angell, Trump Administration Makes It Harder to Track Marijuana Arrests (But I Did
It
Anyway),
FORBES
(Sept.
25,
2017,
2:28
PM),
https://www.forbes.com/sites/tomangell/2017/09/25/trump-administration-makes-it-harder-totrack-marijuana-arrests-but-i-did-it-anyway/#471e4d3e68bc.
117

Tom Angell, Marijuana Arrests Are Increasing Despite Legalization, New FBI Data Shows,
FORBES
(Sept.
24,
2018,
8:33
AM),
https://www.forbes.com/sites/tomangell/2018/09/24/marijuana-arrests-are-increasing-despitelegalization-new-fbi-data-shows/#67acb38d4c4b.
118

Beck, supra note 39. Notably, a law enforcement officer interviewed within the article said
that officers get frustrated because the penalties for cannabis possession aren’t strict enough to
deter use: “First offense is $50 with no jail time, so it’s almost like running a red light.” However,
currently cannabis possession laws are stricter than this would suggest, with the penalty for
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national rate of cannabis related incarceration appears to be increasing,
possession in West Virginia continues to be criminal. As public interest increases
and harm perceptions change, it is likely safe to assume that cannabis related
arrests will continue to be prominent among West Virginia drug arrests.
III. WEST VIRGINIA MEDICAL CANNABIS ACT SUMMARY
The Act extensively regulates the emerging medical cannabis industry
by controlling doctor recommendations and the means of growing, processing,
and dispensing. The Act allows for doctor-recommended cannabis as treatment
for patients’ “[s]erious medical condition[s]” including cancer, HIV, Parkinson’s
disease, epilepsy, post-traumatic stress disorder, neuropathies, multiple sclerosis,
Huntington’s disease, Crohn’s disease, chronic pain, and terminal illnesses.119
Patients with a qualifying condition must apply for an identification card and
present the identification card to an authorized dispensary in order to purchase
medical cannabis.120 Alternatively, the patient is allowed to register a caregiver
who is then able to apply for an identification card and purchase medical
cannabis on behalf of the patient.121 Patients are limited to two registered
caregivers, and caregivers are limited to acting on behalf of up to five patients.122
Both patients and caregivers must have possession of their identification cards
while purchasing or possessing medical cannabis.123 Identification cards for
patients and caregivers may be suspended or revoked upon “intentionally,
knowingly or recklessly” violating any provision of the Act.124 The suspension
or revocation shall occur concurrently with any other criminal penalty that may
apply.125
A. Rules for Growing, Processing, and Dispensing
Dispensaries and patients must follow the Act’s regulations on the forms
of cannabis that can be dispensed. Legal forms currently include pills, oils,

possession being jail time (90 days to six months), fines up to $1,000, or both. See W. VA. CODE
ANN. § 60A-4-401(c) (West 2019).
119

§ 16A-2-1(a)(30). The exhaustive list includes only the following: cancer, HIV,
amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis, damage to the nerve tissue
of the spinal cord, epilepsy, neuropathies, Huntington’s disease, Crohn’s disease, post-traumatic
stress disorder, intractable seizures, sickle cell anemia, chronic pain, and terminal illness. Id.
120
121
122
123
124
125

Id. § 16A-5-1(a)–(c).
Id. § 16A-5-1(c).
Id. § 16A-3-2(a)(4)(5).
Id. § 16A-3-2(a)(7).
Id. § 16A-5-9.
Id.
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topical forms,126 tinctures,127 liquids, and dermal patches.128 Although the Act
grants the Bureau for Public Health within the West Virginia Department of
Health and Human Resources (the “Bureau”) authority to promulgate rules under
the Act,129 the Act expressly prohibits dispensing of dry leaf cannabis and edible
medical cannabis forms, subject to change upon the promulgation of the
Bureau’s rules.130
The Act delegates issuance of growing, processing, and dispensing
permits to the Bureau. However, the approval of permits is limited by the
following: “The [B]ureau may not issue permits to more than 10 growers . . .
more than 10 processors . . . [and] more than 100 dispensaries.”131 Additionally,
the following must be considered by the Bureau when issuing a permit: “(1)
Geographic location; (2) Regional population; (3) The number of patients
suffering from serious medical conditions; (4) The types of serious medical
conditions; (5) Access to public transportation; (6) Approval by local health
departments; (7) [county prohibition]; (8) Any other factor the [B]ureau deems
relevant.”132 Although the Act initially prohibited the vertical integration of
growers, processors, and dispensaries by mandating that “[a] grower or processor
may not be a dispensary,”133 the legislature passed a bill in 2019 that allows for
the vertical integration of growers and processors.134 Individuals can only
possess one grower permit, one processor permit, or two dispensary permits.135
The Act contains a variety of controls aimed at preventing cannabis
diversion into illegal markets. All medical cannabis organizations must
“implement an electronic inventory tracking system which shall be directly
accessible to the [B]ureau through its electronic database that electronically
tracks all medical cannabis on a daily basis.”136 For a grower or processor, this
includes a “seed-to-sale tracking system” which tracks the entire growing

126

Topical forms can include gels, creams, or ointments. Id. § 16A-3-2(a)(2)(C).

127

A tincture is a concentrated liquid herbal remedy generally consumed orally. See Cathy
Wong, What You Need to Know About Herbal Tinctures, VERYWELL HEALTH,
https://www.verywellhealth.com/herbal-tinctures-89393 (last updated Aug. 30, 2019).
128
W. VA. CODE ANN. § 16A-3-2(a)(2).
129
130
131
132
133

Id. § 16A-3-1(b).
Id. § 16A-3-3(b).
Id. § 16A-6-13(a)(1)–(3).
Id. § 16A-6-3(d)(1)–(8).

Id. § 16A-6-13(a)(9) (West 2017) (amended 2019).
See S. 1037, 84th Leg., 1st Extraordinary Sess. (W. Va. 2019); Erin Beck, Lawmakers Pass
Fix to Medical Marijuana Bill, REG.-HERALD (Beckley, W. Va.) (May 20, 2019),
https://www.register-herald.com/news/state_region/lawmakers-pass-fix-to-medical-marijuanabill/article_dbad3657-ba40-546a-a599-ea6d068941b9.html.
135
W. VA. CODE ANN. § 16A-6-13(a)(4)–(6) (West 2017) (amended 2019). Growers may have
up to two locations per permit. Id. § 16A-6-13(a)(1) (West 2019).
136
Id. § 16A-7-1(a).
134
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process through to selling to a dispensary.137 All growing must be done in “an
indoor, enclosed, secure facility [with] . . . electronic locking systems [and]
electronic surveillance.”138 Transporting medical cannabis must be done under
similar regulations; the Act requires the use of GPS and electronic tracking
systems to ensure delivery and receipt recordkeeping while defending against
losses occurring in storage or transit.139 In addition to the security and reporting
regulations, the Act further prevents the criminal diversion of medical cannabis
by creating specific criminal penalties for practitioners, operators, or employees
of medical cannabis organizations.140 The Bureau is empowered by the Act to
“notify any appropriate law-enforcement agency of information relating to any
violation or suspected violation of [the] [A]ct.”141 Additionally, the Bureau shall
verify permits, registrations, or identification cards to law-enforcement
personnel in appropriate cases.142
Dispensaries are subject to further precautionary regulations. Initially,
the Act required “a physician or pharmacist onsite at all times during the hours
the dispensary is open.”143 However, this requirement was removed by the
legislature in 2019. When dispensing to a patient or caregiver, “the dispensary
may not dispense an amount greater than a 30-day supply until the patient has
exhausted all but a seven-day supply.”144 A medical cannabis sale must include
a safety insert which educates patients on “[l]awful methods for administering
medical cannabis[,] . . . potential dangers[,] . . . [h]ow to recognize what may be
problematic usage[,] . . . [and] [h]ow to prevent or deter the misuse of medical
cannabis by minors or others.”145 Medical cannabis must be sold in a sealed and
labeled package which contains health and legal warnings, as well as the
package’s amount of individual doses and percentage of tetrahydrocannabinol
(“THC”) and cannabidiol (“CBD”), as well as the species from which the doses
are derived.146

137
138
139
140
141
142
143
144
145
146

Id. § 16A-7-1(a)(1).
Id. § 16A-7-2(b)(1).
Id. § 16A-7-3.
See id. §§ 16A-12-1 to -9.
Id. § 16A-10-3.
Id.
Id. § 16A-8-1(b) (West 2017) (amended 2019).
Id. § 16A-8-1(d) (West 2019).
Id. § 16A-8-1(g).
Id. § 16A-8-1(h).
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B. Administrative Rules and Requirements
Common with cannabis regulations in other states, the Act contains
specific tax provisions for medical cannabis.147 “A tax is imposed on the gross
receipts of a grower/processor received from the sale of medical cannabis by a
grower/processor to a dispensary, to be paid by the grower/processor, at a rate of
ten percent.”148 This tax has to be “paid by the grower/processor and shall not be
added as a separate charge . . . of the price paid by a dispensary, patient or
caregiver.”149 Further, “[m]edical cannabis shall not be subject to a sales tax.”150
The Act establishes a Medical Cannabis Program Fund to receive the taxes
payable under the act and directs allocation of appropriated funds.151
“Money in the fund is allocated in accordance with the following
percentages”: 55% of the revenue in the fund shall be allocated to the Bureau
with the remaining 45% of the revenue allocated by 50% to the Fight Substance
Abuse Fund, 40% to the Division of Justice and Community Services (for grants
to local law enforcement agencies for training, drug diversion, and other
programs focused on crime and addiction), and 10% to a fund to be used for lawenforcement professional training and professional development programs.152
The Medical Cannabis Advisory Board, created by the Act and located
within the Bureau, is tasked with “analyz[ing] the statutory and regulatory law
relating to medical cannabis within the state . . . and events in other states and
the nation with respect to medical cannabis.”153 Further, “[t]he [Board] shall”
issue a written report to the Governor, the Senate and House of Delegates two
years after the effective date of the Act.154 The report “shall include
recommendations and findings as to” whether to change the types of medical
professionals who can issue certifications to patients; whether to change, add, or
reduce the types of qualifying medical conditions; whether to change the form of
medical cannabis permitted; whether to change, add, or reduce the number of
growers, processors, or dispensaries; and how to ensure affordable patient access
to medical cannabis.155 “After receiving the report of the advisory board, at the
discretion of the commissioner, the [B]ureau may propose rules for legislative
promulgation . . . to effectuate recommendations made by the advisory board.”156

147
148
149
150
151
152
153
154
155
156

Id. § 16A-9-1.
Id. § 16A-9-1(a) (West 2017) (amended 2019).
Id.
Id. § 16A-9-1(d).
Id. § 16A-9-2 (West 2019).
Id. § 16A-9-2(c).
Id. § 16A-11-1(j)(1)–(2).
Id. § 16A-11-1(j)(4).
Id. § 16A-11-1(j)(5)(A)–(E).
Id. § 16A-11-2.
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In addition to the Medical Cannabis Advisory Board, the Act instructs
the Bureau to “establish and develop a research program to study the impact of
medical cannabis on the treatment and symptom management of serious medical
conditions.”157 The program includes “[creating] a database of all serious
medical conditions . . . which are cited by practitioners in the certifications of
patients.”158 Once 25 or more patients with the same serious medical condition
are added to the database, the Bureau shall “petition the United States Food and
Drug Administration [(“FDA”)] and the United States Drug Enforcement
Administration [(“DEA”)] for approval to study the condition and the impact of
medical cannabis on the condition.”159 Concurrent with the FDA and DEA
petitions, the Bureau shall “publicly announce the formation of a research study
to which a vertically integrated health system and a university within this state
may submit a request to participate.”160 The Bureau must also select patients to
participate in the research study and notify each consenting patient “where the
patient may secure medical cannabis . . . at no cost to the patient.”161 “The cost
of the medical cannabis which is dispensed to patients in accordance with an
approved research study shall be paid for by the fund.”162 Further, if the FDA
and DEA reject the proposal for the research study, the Bureau shall “take all
reasonable steps to collect and collate data on the serious medical condition and
the use of medical cannabis as a treatment for the serious medical condition and
consider submitting an additional request . . . for a research study on the same
condition.”163 “A health care medical cannabis organization may not participate
in a research study of any kind, including the program established [by the
Act].”164
The Act offers specific protections for patients and caregivers with
respect to criminal penalties and employment discrimination.165 The Act protects
patients, caregivers, practitioners, and medical cannabis organizations from
being arrested solely for their lawful use action taken in accordance with the
Act.166 Employers are prohibited from discriminating or retaliating against an
157
158

Id. § 16A-13-2(a).
Id. § 16A-13-2(b)(2).

159

Id. § 16A-13-2(b)(3).
Id. § 16A-13-2(b)(4). “Vertically integrated health system” is defined as “[a] health delivery
system in which the complete spectrum of care, including primary and specialty care,
hospitalization and pharmaceutical care, is provided within a single organization.” Id. § 16A-131.
161
Id. § 16A-13-2(b)(6).
160

162

Id. § 16A-13-2(c) (referring to the fund created by the Act which receives 55% of medical
cannabis tax revenue).
163
164
165
166

Id. § 16A-13-2(b)(7).
Id. § 16A-13-6.
Id. § 16A-15-4.
Id.
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employee “solely on the basis of such employee’s status as an individual who is
certified to use medical cannabis.”167 However, the Act expressly does not
“require an employer to make any accommodation of the use of medical cannabis
on the property or premises of any place of employment.”168 Further, the Act “in
no way limit[s] an employer’s ability to discipline an employee for being under
the influence of medical cannabis in the workplace . . . when the employee’s
conduct falls below the standard of care normally accepted for that position.”169
C. The Medical Cannabis Advisory Board Recommends Broader
Applicability with Fewer Restrictions, Including Allowing Dry Leaf
Cannabis
Pursuant to its duty under the Act, the Medical Cannabis Advisory Board
published a collection of findings and seven recommendations in February
2018.170 Those recommendations include the following: Recommendation 1.1
would “[a]mend the Act to clarify requirements and responsibilities for
physicians who issue certifications”; Recommendation 1.2 would “[r]eplace the
phrase ‘Serious Medical Conditions’ with the phrase ‘Medical Conditions with
Possible Serious Manifestations’ throughout”; Recommendation 2.1 would
“[i]nclude dry leaf or plant form medical cannabis medically appropriate for
administration by vaporization or nebulization”; Recommendation 3.1 would
“[r]emove limitations on the number of permits the Bureau for Public Health
may issue for growers, processors, and dispensaries”; Recommendation 3.2
would “[r]emove limitation that a grower or processor may not also be a
dispensary to permit the vertical integration of growers, processors and
dispensaries”; Recommendation 3.3 urges the legislature to “evaluate the need
for the requirement that a physician or pharmacist must be onsite at all times
during the hours the dispensary is open to receive patients”; and
Recommendation 3.4 encourages authorization of “a pre-registration process for
potential medical cannabis patients to more clearly ascertain the market interest
within West Virginia.”171
The legislature considered various amendments to the Act a year after
its passage. Senate Bill 487 was considered and ultimately rejected during the
2018 legislative session.172 The proposal would have amended the Act to allow
dry leaf cannabis dispersion without requiring a new rule promulgated by the

167
168

Id. § 16A-15-4(b)(1).
Id. § 16A-15-4(b)(2).

169

Id.
W. VA. MED. CANNABIS ADVISORY BD., REPORT AND RECOMMENDATIONS 4 (2018),
https://dhhr.wv.gov/bph/Documents/MedicalCannabis/MCAB%20Report%20Recommendations
%20FINAL%2002.22.2018.pdf.
170

171
172

Id.
See S. 487, 83d Leg., Reg. Sess. (W. Va. 2018).
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Bureau.173 Additionally, the amendment would restructure application fees and
allow the delivery of medical cannabis by a dispensary to qualifying patients.174
The legislature also considered and rejected a bill which would have
significantly reduced the stringent restrictions currently placed on permit
issuance. House Bill 4345 sought to increase the permits available to 50 for
growers, 50 for processors, and 165 for dispensaries.175 House Bill 4345 also
would have allowed for the vertical integration of growing, processing, and
dispensing.176
Changes to the dry leaf prohibition and permit limitations were both
supported by the state’s Medical Cannabis Advisory Board.177 In fact, the
Advisory Board recommended eliminating the limitations on number of permits
issued entirely.178 The Board noted that while
[t]he work group is not currently in a position to recommend a
specific number for the increase [in permits] . . . work group
members believe the current numbers are likely too low to
provide for adequate patient access and market viability in light
of . . . interest level that has been indicated thus far.179
The Board also noted that “by increasing the number of permits
available, a broader cross-section of interested businesses would be able to take
part in the process allowing for an increase in affordable patient access to
medical cannabis.”180 Lastly, the Board noted, in furtherance of its concern for
the economics of medical cannabis in West Virginia, that
it appears West Virginia is an outlier in prohibiting vertical
integration among the 29 states that have approved medical
cannabis laws. . . . [I]t seems that the [prohibition on vertical
integration] currently provided in the law would make it less
economically viable for entities to enter into this market and to
provide an affordable product for patients.181
The legislature addressed the vertical integration issue in its 2019 session
by passing House Bill 2079. The bill would have allowed for vertical

173
174
175
176

Id.
Id.
H.D. 4345, 83d Leg., Reg. Sess. (W. Va. 2018).
Id.

177

W. VA. MED. CANNABIS ADVISORY BD., supra note 170, at 7.
Id. (“Recommendation 3.1: Remove limitations on the number of permits the Bureau for
Public Health may issue for growers, processors, and dispensaries.”).
179
Id.
178

180
181

Id. (emphasis added).
Id. at 7–8.
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integration—one person could hold any combination of grower, processor, and
dispensary permits. The bill was purportedly an effort to attract medical cannabis
businesses to West Virginia.182 The bill also allowed for chronic pain patients to
use medical marijuana without having to try an opioid first.183 The legislature
also passed House Bill 2538 in its 2019 session, which allows credit unions to
accept medical cannabis revenue.184 But the legislature did not amend restrictions
on the forms of cannabis that patients can use.
IV. COMPARISON OF CANNABIS LAW AND POLICY ACROSS THE STATES
West Virginia stands out among the Appalachian states as one of four
states with a comprehensive medical cannabis program.185 Maryland,
Pennsylvania, and Ohio also have comprehensive programs, while the rest of the
Appalachian states allow CBD or low-THC medical cannabis products.186 Like
West Virginia, Ohio’s strict regulations surrounding medical cannabis led to
speculation on the potentially high cost of patient participation in the program.187
Ohio’s $472 average per ounce price of medical cannabis essentially affirmed
the accuracy of such speculation.188 This Part will attempt to analyze regulations
and medical cannabis pricing because in many cases pricing could present a
significant barrier for patients attempting to enter the market.189 However, it must
be noted that in some jurisdictions’ patient reporting may have to be relied upon
for price data. Further, estimating dosage is a significant factor when estimating
how much a patient may spend on medical cannabis, but medical cannabis users

182

Erin Beck, Bill to Bring Medical Marijuana Businesses to West Virginia Heads to Governor,
REG.-HERALD
(Beckley,
W.
Va.)
(Mar.
9,
2019),
https://www.registerherald.com/news/state_region/bill-to-bring-medical-marijuana-businesses-to-west-virginiaheads/article_d51a6aaa-2ca1-59c8-bc67-2df4164b444c.html. Delegate Cindy Lavender-Bowe
explained, “I signed onto the bill because I want to make medical marijuana available ASAP in
West Virginia to give patients the relief they need.” Id. Delegate Mike Pushkin further stated the
bill is “the biggest jobs-creating bill that we have this session.” Id.
183
Id.
184
185
186

Id.
State Medical Marijuana Laws, supra note 5.

Id.
See Bill Hormann, What to Know About Ohio’s Medical Marijuana Program, 13ABC
WTVG TV (Oct. 20, 2018, 2:55 PM), https://www.13abc.com/content/news/What-to-know-aboutOhios-medical-marijuana-program-498111601.html (“[R]ules includ[ing] packaging each daily
dose separately . . . will drive up prices . . . .”).
188
See Jackie Borchardt, Why Aren’t Ohioans Rushing to Buy Medical Marijuana?,
CINCINNATI
ENQUIRER
(Mar.
25,
2019,
10:11
PM),
https://www.cincinnati.com/story/news/2019/03/25/why-arent-ohioans-rushing-buy-medicalmarijuana/3205803002/.
189
See W. VA. MED. CANNABIS ADVISORY BD., supra note 170, at 8.
187
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can have substantially different dosage needs190 and dosage is most often
discussed in terms of grams of dried flower, which is prohibited in West Virginia.
Maryland does not restrict the dispersion of dry leaf cannabis and allows
patients to smoke or vaporize on private property.191 Nor does Maryland prohibit
the vertical integration of cannabis growers, processors, and dispensaries.192
Maryland has retained criminal penalties for possessing cannabis outside of its
medical program.193 The law commands the Maryland Commission to “actively
seek to achieve racial, ethnic, gender, and geographic diversity when licensing
medical cannabis growers.”194 The Commission is empowered to license as many
growers as is necessary to meet demand, but was initially limited to 15 licensed
growers.195 Maryland law does not require the presence of a licensed physician
onsite.
The Baltimore Sun estimates that 3.5 grams of Maryland medical
cannabis (one eighth of an ounce) costs about $50–$60.196 The same amount is
estimated to cost an average of $40 throughout the national market.197 However,
patients have reported prices up to $84 per 3.5 grams.198 The estimated Maryland

190
See Dustin Sulak, A Physician’s Perspective on Optimal Cannabis Dosing, LEAFLY (Feb.
26, 2018), https://www.leafly.com/news/health/a-physicians-perspective-on-optimal-cannabisdosing (describing the unusually large dosing-range for medical cannabis and describing the lowest
therapeutic dose as optimal); see also Dosing and Delivery of CanniMed Medical Cannabis,
CANNIMED, https://www.cannimed.ca/pages/dosing-and-delivery (last visited Sept. 9, 2019). A
Canadian medical cannabis company (responsible for the first sale of medical cannabis in the
country in 2001 through a deal with the Canadian government) suggests that the average medical
dose per day is 1–3 grams of dried flower and that 0.78 grams of dried flower is equivalent to
approximately 60 mL of (this particular company’s) oil. Id.
191
192
193
194

See MD. CODE ANN., HEALTH–GEN. § 13-3314 (West 2019).
Id. § 13-3314(e).
See id. § 13-3313(b)(1).
Id. § 13-3306(a)(9)(i)(1).

195
See DEP’T OF LEGISLATIVE SERVS., FISCAL AND POLICY NOTE, S. 37, 2018 Gen. Assemb.,
Reg. Sess., at 5 (Md. 2018); see also Larisa E. Bolivar, Medical Cannabis Policy in Maryland:
Proposed Number of Cannabis Grow Licenses Will Not Meet Demand, CANNABIS CONSUMERS
COALITION (Jan. 19, 2016), https://www.cannabisconsumer.org/medical-cannabis-policy-inmaryland-proposed-number-of-cannabis-grow-licenses-will-not-meet-demand.html (predicting
that 15 licenses was “far from sufficient” to meet consumer demand).
196

Sarah Meehan, FAQ: What You Need to Know About Medical Marijuana in Maryland,
BALT. SUN (Mar. 20, 2018, 5:30 PM), https://www.baltimoresun.com/health/marijuana/bs-mdmedical-marijuana-faq-20171207-story.html.
197
Priceonomics, Here’s How Much Marijuana Costs in the United States vs Canada, FORBES
(May 18, 2018, 12:52 PM), https://www.forbes.com/sites/priceonomics/2018/05/18/heres-howmuch-marijuana-costs-in-the-united-states-vs-canada/#764179bf538a.
198

See
Reviews
of
Allegany
Medical
Marijuana
Dispensary,
GOOGLE,
https://www.google.com (last visited Sept. 9, 2019) (search “Allegany Medical Marijuana
Dispensary,” then click the “Google reviews” hyperlink) (reporting high prices and alleging that
the owner actually bans patients who post or complain about the price).
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street cost of similar quality cannabis is about $40.199 Thus, an apparently
conservative daily dose of 0.5 grams in Maryland could cost consumers
anywhere from $7.10 to $12. A consumer with higher dosage needs could expect
to pay three to five times that range, resulting in a potential $60 daily medicine
bill.
Pennsylvania’s program has many regulations that are similar to West
Virginia’s. An exhaustive list of qualifying medical conditions is expressly
enumerated, and similar to that of West Virginia’s.200 The statute also prohibits
dispersion of dry leaf cannabis, subject to change as regulations are adopted by
the department.201 The Department of Health currently allows dry leaf dispersion,
but only for vaporization.202 Smoking medical cannabis is still prohibited.
Pennsylvania’s scheme differs from West Virginia’s with respect to its tax
allocations. The Department of Health receives 55% of the tax revenue created
by the Act.203 The majority of the funding received by the Department (40%) is
expended by the Department for operations relating to the Act; the remaining
15% is dedicated to assisting patients who demonstrate financial need with the
cost of medical cannabis, as well as costs associated with identification cards and
background checks.204 The remainder of the fund is divided between the
Department of Drug and Alcohol Programs (for drug abuse prevention,
counseling, and treatment services) with 10%, further research related to medical
cannabis with 30%, and the Pennsylvania Commission on Crime and
Delinquency with only 5%.205 Pennsylvania does not require the presence of a
physician at every dispensary location.206 Currently, possession of small amounts
of cannabis (less than 30 grams) without intent to sell is a misdemeanor
punishable by up 30 days in jail and a $500 fine.207
Before the Department of Health began allowing dry leaf form, medical
cannabis had to be purchased in processed forms such as wax or oil

199

Maryland Weed Prices, BUDZU, http://budzu.com/prices/usa/maryland (last visited Sept. 9,
2019) (relying on anonymous user submissions for data).
200
201

See 35 PA. STAT. AND CONS. STAT. ANN. § 10231.103 (West 2019).
See id. § 10231.303(b)(3).

Patients
and
Caregivers,
PA.
DEP’T
HEALTH,
https://www.health.pa.gov/topics/programs/Medical%20Marijuana/Pages/Patients.aspx
(last
visited Sept. 9, 2019).
203
See 35 PA. STAT. AND CONS. STAT. ANN. § 10231.902(c)(1).
202

204
205
206
207

See id.
Id. § 10231.902(c)(2)–(4).
See id. § 10231.801(b).
Id. § 780-113(g).
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concentrates208 for up to $75 per gram.209 The price of dry leaf cannabis after its
prohibition was lifted is approximately $35 per 3.5 grams.210
Although California was the first state to recognize medical cannabis in
1996, Colorado was the first state to develop a regulated commercial market for
medical cannabis in 2010.211 Prior to the passage of Colorado’s act to regulate
medical cannabis, the state’s constitution was amended in 1999 to exempt
caregivers and patients from criminal penalties for engaging in or assisting in the
use of medical cannabis, without establishing a state licensed and regulated
market.212 Amendment 64, which legalized recreation marijuana sales, was
passed in 2012 only two years after the establishment of the regulated medical
market.213 Possession of less than two ounces of cannabis was decriminalized in
1975, making such possession punishable by a fine of $100 or less when the
regulated medical market was established.214
Colorado’s 2010 act establishing medical cannabis regulations
significantly contrasts with West Virginia’s approach. Dry leaf and flower sales
are not prohibited,215 patient cultivation of cannabis plants is expressly
allowed,216 and local county or municipal governments are able to develop their
own licensing restrictions in addition to the statewide licensing rules.217 In fact,
local governments even have the power to prohibit operation of medical cannabis
facilities, including dispensaries.218 Under the House Bill, up to one million

208

Concentrates contain higher percentages of THC or CBD, and therefore the estimated 1–3
gram medical dosing average of flower is not directly applicable. See What You Should Know
About Marijuana Concentrates/Honey Butane Oil, GET SMART ABOUT DRUGS (Aug. 8, 2018)
https://www.getsmartaboutdrugs.gov/content/what-you-should-know-about-marijuanaconcentrates-honey-butane-oil. Notably, encouraging concentrates by prohibiting flower may
actually make finding the optimal lowest therapeutic dose more difficult for patients because the
product is so much stronger.
209
Ben Schmitt, How Much Is Medical Marijuana in Pennsylvania? Prices Are Coming into
Focus, PITT. TRIB.-REV. (Feb. 16, 2018, 2:33 PM), https://triblive.com/news/healthnow/1331306974/how-much-is-medical-marijuana-in-pennsylvania-prices-are-coming-into-focus.
210

David Wenner, Pa. Begins Dry Leaf Medical Marijuana Sales, Reminds Users Not to Smoke
It,
PATRIOT-NEWS
(Harrisburg,
Pa.)
(Aug.
1,
2018),
https://www.pennlive.com/news/2018/08/pa_begins_dry_leaf_medical_mar.html.
(“Terrapin
Pennsylvania, a grower-processor, said this week that dry leaf will sell for as little as $10 a gram.”).
211
212
213
214

See H.R. 1284, 67th Gen. Assemb., 2d Reg. Sess. (Colo. 2010).
COLO. CONST. art. XVIII, § 14(2)(b)–(c).
See id. § 16.
COLO. REV. STAT. ANN. § 18-18-406(1) (West 2012) (repealed 2013).

215

See id. § 25-1.5-106(12) (West 2019).
See id. § 25-1.5-106(8.5) (“All patients cultivating more than six medical marijuana plants
for their own medical use are encouraged to register with the state licensing authority’s
registry . . . .”).
216

217
218

Id. § 25-1.5-106(13.5).
See H.R. 1284, 67th Gen. Assemb., 2d Reg. Sess. (Colo. 2010).
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dollars in initial tax revenue was “appropriated to the Department of Human
Services to be used to provide integrated behavioral health services for juveniles
and adults with substance use disorders and mental health treatment needs who
are involved with, or at risk of involvement with, the criminal justice system.”219
Currently, Colorado medical cannabis tax revenues are distributed entirely to a
public school fund and public school capital construction assistance fund.220
Colorado’s medical cannabis market, being the first of its kind in the
United States and given its relatively loose restrictions (when compared to
subsequent developments east of the Mississippi), provided patients with easier
access to their medical supply. Prices of medical cannabis in 2011 ranged
between $25 to $50 dollars per 3.5 grams depending on supply and quality of
product.221
Of the 33 states that have established comprehensive medical cannabis
programs (programs that do allow for medical access to THC products), 11 also
allow adult recreational use.222 Unsurprisingly, the 11 states allowing adult use
also permit dry leaf cannabis to be dispensed to medical patients. Of the
remaining 22 states with a comprehensive medical program, 20 allow dry leaf
cannabis dispersion in at least some circumstances.223 Louisiana and
Minnesota224 are the only two states besides West Virginia that have established
a comprehensive medical cannabis program but retain a blanket prohibition on
dry leaf dispersion.225

219
220

Id. (amending § 39-26-123).
COLO. REV. STAT. ANN. § 39-28.8-305.

221

See Walt Hickey, The True Story of the Great Marijuana Crash of 2011, BUS. INSIDER (Sept.
25, 2013, 8:00 PM), https://www.businessinsider.com/the-great-marijuana-crash-of-2011-2013-9.
222

See State Medical Marijuana Laws, supra note 5 (Alaska, Washington, Oregon, California,
Nevada, Colorado, Michigan, Vermont, Maine, Illinois, and Massachusetts).
223

See id. North Dakota requires a physician recommendation for patient dry leaf access. N.D.
CENT. CODE ANN. § 19-24.1-21(4) (West 2019). Utah prohibits dry leaf dispersion unless it is sold
in a single dose “blister pack” containing no more than one gram of flower. See UTAH CODE ANN.
§ 26-61a-502(5)(c) (West 2019). New York and Pennsylvania permit dry leaf dispersion but
prohibit smoking.
224
Some Minnesota patients report that the highly regulated program costs them “hundreds or
even thousands of dollars a month, none of it covered by insurance.” Cost of Medical Marijuana
in Minnesota Leads Some to Return to Illegal Sources, GUARDIAN (London) (Sept. 20, 2015, 1:23
PM),
https://www.theguardian.com/us-news/2015/sep/20/cost-of-medical-marijuana-inminnesota-leads-some-to-return-to-illegal-sources.
225

See LA. STAT. ANN. § 40:1046 (West 2019); see also Overview of the Louisiana Therapeutic
Marijuana Act, MARIJUANA POL’Y PROJECT, https://www.mpp.org/states/louisiana/overview-oflouisianas-medical-cannabis-law/ (last visited Sept. 9, 2019). Louisiana appears unique in that it
only allows state universities to grow medical cannabis. See General Information About the
Minnesota
Medical
Cannabis
Program,
MINN.
DEP’T
HEALTH,
https://www.health.state.mn.us/people/cannabis/about/factsheet.html (last visited Sept. 9, 2019).
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V. INCREASING THE EFFICACY OF THE ACT BY ALLOWING DRY LEAF
AND REDUCING UNNECESSARY RESTRICTIONS
Governor Jim Justice described West Virginia’s Medical Cannabis Act
as a compassionate effort to “help our neighbors who are struggling with
illness.”226 Given the capacity of medical cannabis to significantly aid our
struggling neighbors, this Author agrees. However, there are remaining policy
considerations which could further aid chronically ill West Virginians by
reducing market barriers, as well as provide the rest of the state with tangential
benefits. Additionally, the state should consider how a robust cannabis
marketplace can help generate useful revenue.
A. Current Restrictions May Price West Virginia Patients Out of the
Market; Loosening Restrictions and Allowing Dry Leaf Cannabis Will
Help Patients Access Treatment
West Virginia’s medical cannabis laws are some of the strictest in the
country. West Virginia appears to be unique among states recognizing medical
cannabis in its requirement to have a physician onsite during dispensary hours of
operation. Further, its prohibition on dry leaf material is a small minority rule
among the states with operational medical cannabis programs. These factors,
combined with strict limitations on the number of growing licenses available,
may operate to reduce supply and increase prices such that many or most West
Virginian patients simply cannot afford their medicine.
West Virginia’s relatively conservative policies behind the Medical
Cannabis Act are indicative of the “fear” and “mystery”227 that has historically
surrounded the cannabis plant. The state’s concerns regarding potential cannabis
misuse and teen use are not illegitimate concerns and are likely fueled in part by
the havoc opioids have wreaked within the state. However, a holistic review of
the data suggests that while a certain amount of legislative caution is warranted,
the most stringent restrictions are unnecessary to prevent cannabis misuse, traffic
accident increases, and teen use increases.
As described in Part III, medical cannabis prices have a very wide range
and are sensitive to policies operating within the market. In order to fully provide
compassionate use options to chronically ill West Virginians, the state should
seriously consider the Medical Cannabis Advisory Board’s recommendations

226

See Press Release, W. Va. Office of the Governor, Justice Signs Medical Cannabis Bill into
Law (Apr. 19, 2017), https://governor.wv.gov/News/press-releases/2017/Pages/Justice-SignsMedical-Cannabis-Bill-Into-Law.aspx.
227
See Zuckerman, supra note 38. In reference to the amendment restricting available forms,
Judiciary Chairman John Shott said, “We can basically prevent its abuse, and at the same time
provide help to people who need it.” Kalea Gunderson, Amendment to West Virginia Medical
Marijuana Bill Restricts Uses, EYEWITNESS NEWS WCHS TV (Apr. 3, 2017),
https://wchstv.com/news/local/amendment-to-wv-medical-cannabis-act-restricts-marijuana-uses.
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with respect to increasing patients’ potential to access medical cannabis.
Otherwise, patients may be unnecessarily foreclosed from trying a physician
recommended medicine, or worse, encouraged to enter the ever-present black
market.
Fortunately, it seems that the legislature realized that an onsite
physician’s services could be easily replaced by mandatory inserts and labeling
that provide patients with health and safety information.228 This should
significantly reduce dispensary operating costs, thus reducing the price of
medical cannabis products. Further, prohibiting dry leaf dispersion is likely
unnecessary and to some degree counter-intuitive. For instance, if West
Virginia’s policies are reflective of concerns over the drug’s potential misuse,
then why would West Virginia disallow the most natural form of the medicine
and encourage the use of processed extracts that are generally significantly more
potent?229 This policy choice is especially questionable given that prohibiting dry
leaf and requiring processed products will likely increase potential incentive for
diversion into the black market. If processed products are valued higher, and less
available in the black market than dry leaf, it follows that the economic
motivation for diversion will be stronger for concentrated cannabis products.
Requiring cannabis to be processed before being sold will logically serve
to increase product price. Presumably West Virginia does not want to encourage
smoking among chronically ill patients, but other states allow dry leaf while still
prohibiting smoking. Further, there are some scenarios where patients may not
even be able to orally ingest medicine such as late-stage chemotherapy patients.
In such scenarios, a more flexible rule, such as North Dakota’s, which would at
least allow for the dispersion of dry leaf cannabis to patients that have real need
(medical or financial) for vaporization (as recognized by a physician) would be
optimal. Lastly, given West Virginia’s high cancer and opioid prescription rates,
the demand for medical cannabis could be significant. However, as the Medical
Cannabis Advisory Board points out, the limited number of growers, processors,
and dispensaries may not be able to produce supply to meet the demand, thus
potentially further increasing the price of medical cannabis products.

228

For a comprehensive example of labeling requirements which are aimed at warning and
informing patients, see OR. LIQUOR CONTROL COMM’N, PACKAGING AND LABELING GUIDE FOR
MEDICAL
AND
RECREATIONAL
MARIJUANA
–
VERSION
4.0
(2018),
https://www.oregon.gov/olcc/marijuana/Documents/Packaging_Labeling/PackagingandLabeling
Guide.pdf.
229
See supra text accompanying note 208.

2019]

FORBIDDEN FLOWER

285

B. Increasing the Efficacy of the Medical Cannabis Act and Deprioritizing
Criminal Law Enforcement Spending Would Be Economically Beneficial
to West Virginia
Increasing patient access can create a robust marketplace which provides
West Virginia residents with new opportunities for meaningful employment.
Cannabis growing, processing, and dispensing is a labor-intensive industry
which has significant economic impact in areas that allow it.230
Tax revenue is one the most frequently recognized and cited benefits to
establishing a regulated cannabis market, medical or recreational. Yet West
Virginia’s Medical Cannabis Act provides the public with little to no benefit by
failing to distribute any medical cannabis tax revenue into publicly useful funds,
such as Colorado does with its public-school funds.231 Instead, the tax revenue is
used to further enforce criminal prohibition which has largely been unsuccessful
throughout the nation.
Prioritizing criminal law enforcement is further evidence of policy
choices that are reflective of outdated fears surrounding cannabis. When
considering how to prioritize spending, the state should rely not on “intuitions”232
about the plant’s dangers, but rather the data available. Concerns over traffic
safety appear to be largely overblown.233 Increases in money and transient
population associated with cannabis within legal states tend to explain crime rate
increases better than the cannabis plant’s psychoactive effect.234 Teenage use is
a real concern, but criminalization seems an inadequate solution to the problem
because it fails to deter use.235
Further, with so many states and countries drastically reforming
cannabis laws in 2018, and the media aggressively covering the reform, exposure
to cannabis information is higher than ever. The year 2019 is predicted to follow
the same trajectory. In an environment where access and exposure to cannabis
information are ballooning, attempting to maintain any “fear” and “mystery”
surrounding cannabis through criminalization is an antiquated notion of
Appalachian isolationism. The public’s perception of harm has already decreased
230

See supra Part II.

231

See COLO. REV. STAT. ANN. § 39-28.8-305 (West 2019).
See supra text accompanying note 38.

232
233
234

See supra text accompanying note 65.
See McLean & Weisfeldt, supra note 70.

235
Of the two strongest factors for predicting teen use, access and perception of harm, the state
has the best chance at controlling access. Continued criminalization will likely do little to alter
teens’ perception of harm, especially when compared to the impact the media has on teens’
perceptions. Access doesn’t appear to be greatly impacted by criminalization, either, given the fact
that stricter cannabis laws have not reduced cannabis-related charges. However, teenage access
could be restricted by replacing the black market with a robust but tightly regulated market that
could ensure cannabis suppliers within the community only sold to those with identification who
are over 21.
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dramatically compared to decades ago,236 and the current national trends point
towards further social acceptance throughout the country.237 This will surely
impact West Virginian’s perceptions as well. Further, in the near future West
Virginians may have the opportunity to purchase legal cannabis in a bordering
state.238 Given the current environment, spending the Act’s revenue on
maintaining legally enforced prohibition seems like an insurmountable uphill
battle.
If the Act’s regulations and restrictions were reduced to a degree which
allows supply to meet demand, and product prices are within a range that the
consuming population can generally afford, then the medicinal market created
by the Act could help fund the public teacher pay raise that is recommended by
the West Virginia Center on Budget and Policy as a tool to combat the state’s
economic status.239 Alternatively, West Virginia could follow the lead of
Pennsylvania’s medical cannabis program which funds alcohol and drug abuse
prevention programs at a higher rate than traditional law enforcement
mechanisms. Regardless of the route, West Virginia has the opportunity to
increase the public’s tangential benefits by prioritizing public use funding over
continuing the current criminal law enforcement status quo.
VI. CONCLUSION
The Medical Cannabis Act grants patients like Rusty Williams who are
chronically or terminally ill access to carefully restricted medical cannabis.
Medical cannabis is a promising alternative treatment to many of the chronic
ailments afflicting West Virginians. However, the tight regulations stemming
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The internet has been one of reform advocates’ greatest tools for releasing data and
countering old perceptions. See DEANGELO, supra note 10, at 168.
Jolene Forma, senior staff attorney at the Drug Policy Alliance told Newsweek, “In 2019, I
think we can expect to see more of the same type of change, but maybe at a more rapid pace.”
Alexandra Hutzler, Marijuana Legalization 2019: Which States Will Consider Legal Weed in Year
Experts Predict Will Be ‘Real Game-Changer’, NEWSWEEK (Jan. 1, 2019, 8:10 AM),
https://www.newsweek.com/which-states-legalization-marijuana-2019-1275736 (“The train has
left the station. Americans of all political affiliations and almost all demographics support
marijuana legalization.”).
238
Maryland lawmakers claim legalizing cannabis is on the agenda for the new year’s
legislative session. Kate Ryan, Legalizing Marijuana, Banning ‘Ghost Guns’ on To-Do List for
Md.
Lawmakers,
WTOP-FM
(Jan
1,
2019,
6:00
PM),
https://wtop.com/maryland/2019/01/maryland-legislative-session-starts-in-one-week/.
Pennsylvania Governor Tom Wolf, previously opposed to legalization, “now says that he’s ready
to take a serious look at the issue [and] also supports moving ahead immediately with less farreaching moves to decriminalize cannabis possession.” Tom Angell, These States Are Most Likely
to
Legalize
Marijuana
in
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(Dec.
26, 2018, 2:11 PM),
https://www.forbes.com/sites/tomangell/2018/12/26/these-states-are-most-likely-to-legalizemarijuana-in-2019/.
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See WORKING WEST VIRGINIA, supra note 113.
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from outdated perceptions will likely serve to make medical cannabis
inaccessible to at least some West Virginian patients and could potentially create
an unnecessary financial burden for many more. These concerns would likely be
reduced by adopting the Medical Cannabis Advisory Board’s recommendations,
following the majority of other states by allowing dry leaf dispersion, increasing
available permits, and lifting the onsite physician requirement for dispensaries.
Easing the restrictions and creating a more robust medical cannabis market could
also serve the rest of the population by creating a new source of public use
revenue if criminal prohibition is de-prioritized by the state. A review of
outcomes in states with robust medical or recreational marketplaces does not
support the need for regulations as tight as West Virginia’s. Instead, the benefits
of creating a robust marketplace appear to consistently outweigh costs,
explaining the incredible rate of cannabis reform throughout the nation.
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